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ABSTRACT
Objective: Several glucagon-like peptide-1 (GLP-1)
receptor agonists (GLP-1Ra) have been made recently
available in Spain for type 2 diabetes mellitus (DM2)
treatment. There are no published data on the clinical
and sociodemographic profile of patients initiating
treatment with GLP-1Ra in Spain. Our objective was to
understand these patients’ characteristics in a
real-world clinical practice setting.
Design: Cross-sectional observational study.
Setting: Spanish specialist outpatient clinics.
Participants: 403 adults with DM2 initiating GLP-1Ra
treatment were included.
Primary and secondary outcome measures:
Sociodemographic and DM2-related clinical data,
including treatment at and after GLP-1Ra initiation and
comorbidities, were collected.
Results: Evaluable patients (n=403; 50.9% female)
were included ( July 2013 to March 2014) at 24
centres by 53 specialists (47 endocrinology, 6 internal
medicine), with the following profile (value±SD): age
(58.3±10.4 years), diabetes duration (9.9±7 years),
body mass index (BMI; 36.2±5.5) and glycated
haemoglobin (HbA1c; 8.4±1.4%); 14% had
HbA1c≤7%. Previous antidiabetic treatment: 53.8%
only oral antidiabetic drugs (OADs), 5.2% insulin and
40% insulin and OAD; of those receiving OAD, 35%
single drug, 38.2% 2 drugs and 24% 3 drugs.
Concomitant to GLP-1Ra, 55.3% were only on OAD,
36.2% on insulin and OAD, and 7.2% only on insulin.
Of those receiving OAD, the GLP-1Ra was mainly
associated with 1 drug (65%) or 2 drugs (31.8%).
GLP-1Ra are frequently added to existing antidiabetic
drugs, with dipeptidyl peptidase-4 inhibitors being the
OAD most frequently switched (45% receiving 1 before
starting GLP-1Ra, only 2.7% receiving it
concomitantly).
Conclusions: In Spain, GLP-1Ra therapy is usually
started in combination with OADs or OADs and insulin.
These drugs are used in relatively young patients often
not reaching therapeutic goals with other treatment
combinations, roughly a decade after diagnosis and
with a relatively high BMI. The latter could be explained
by Spanish regional payers limiting reimbursed
prescription to patients with a minimum BMI threshold
(>30 in most regions, >35 in some).
INTRODUCTION
Type 2 diabetes mellitus (DM2) is a chronic
metabolic disorder with worldwide steadily
increasing prevalence that is expected to
grow in all age groups worldwide from 2.8%
in 2000 to 4.4% in 2030.1 In Spain, the
overall prevalence of diabetes mellitus in
adults adjusted for age and sex was estimated
in a representative sample of the population
to be 13.8%, of which about half (6.0%) had
unknown diabetes2 and, considering the
Spanish population, the number of patients
with diagnosed diabetes (treated or
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first
cross-sectional effort trying to find out the pro-
files of patients receiving initial prescriptions of
glucagon-like peptide-1 receptor agonists
(GLP-1Ra), since efforts so far have been largely
limited to retrospective analyses or physician
surveys.
▪ The study sample is fairly representative of the
overall Spanish population of patients with type
2 diabetes mellitus.
▪ The reason for treatment change was not
recorded. Therefore, the reasons for prescribing
GLP-1Ra cannot be fully ascertained.
▪ Payers’ restrictions to GLP-1Ra in Spain resulted
in first prescription being mainly done by specia-
lists, which may have resulted in some patient
selection bias towards a more advanced,
complex patient type.
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untreated with drugs) may be estimated to be over 3.6
million people. Total (known and unknown) DM2 preva-
lence in Spain was estimated at 15.3% in men and
14.2% in women.3
The short-term aim of therapy for hyperglycaemia is
improved blood glucose control without signiﬁcant toler-
ability or safety issues, and with the longer term objective
of reducing vascular damage. Although most initial
pharmacological therapies include an oral glucose-
lowering agent, a steady decline in islet β-cell function
results in progressive hyperglycaemia, which requires a
stepwise escalation of treatment. Eventually, insulin is
often required as the only therapy independent of the
need for endogenous insulin production. Glucagon-like
peptide-1 receptor agonists (GLP-1Ra) have recently
become a therapeutic option. GLP-1Ra mimic, at supra-
physiological levels, the action of endogenous GLP-1, in
stimulating glucose-dependent insulin secretion and by
suppressing glucagon secretion. Gastric emptying is
delayed, especially in the early weeks of therapy. This, and
perhaps a direct or indirect hypothalamic action, results in
appetite/satiety changes and thus loss of body weight.4
Despite being on the market since several years, little is
known about the characteristics of patients treated with
GLP-1Ra and about the place of these drugs in DM2 in
the real-life setting. In fact, we could not ﬁnd any pro-
spective study aiming at ﬁnding out these aspects, which
may be quite relevant. The published literature includes
several efforts using retrospective analyses of existing
databases4–7 or physician surveys.8 Furthermore, current
available databases do not provide this information for
patients in Spain and in most other countries. Hence, the
present cross-sectional study was conducted in a real prac-
tice environment with the objective of ﬁnding and
describing the demographic and clinical characteristics
of patients with DM2 who receive initial prescriptions of a
GLP-1Ra in Spain for the treatment of DM2 and, as such,
constitutes a novel approach which may be valuable in
learning about the patient proﬁles and the decision
drivers of treating physicians to initiate therapy with a
GLP-1Ra, something which indeed may vary depending
on the countries and circumstances.
PATIENTS AND METHODS
Study design
This was a cross-sectional, observational, non-
interventional, multicentre study conducted in adult
patients with DM2 newly treated with GLP-1Ra in Spanish
specialist outpatient clinics, since these drugs are mostly
initiated in Spain by specialists. The study was approved
by Research Ethics Committees from participating
centres and was conducted according to the Declaration
of Helsinki. All patients signed informed consent.
Study population
Participating physicians were invited to record character-
istics of consecutive patients attending outpatient
specialist clinics since in Spain initial prescriptions of
GLP-1Ra are mostly made by specialists across the
country. Patients were included in the study if they: (1)
were adults (≥18 years old) presenting with DM2 and
visiting the investigator for any reason; (2) were pre-
scribed for the ﬁrst time a GLP-1Ra on the day of inclu-
sion in the normal course of care, or who had initiated
GLP-1Ra therapy within 3 months before the inclusion
visit (as long as the study required information was avail-
able); and (3) provided informed consent in writing to
participate. Candidate patients were excluded if they
were participating in a study with an investigational drug
or procedure.
A sample size of 384 patients was required in order to
estimate in the study population, with a CI (95%) of
±5%, a 50% proportion of one of the two main criteria
of interest, body mass index (BMI) or glycated haemo-
globin (HbA1c) level at initiation of GLP-1Ra therapy.
Assuming a 5% rate of non-evaluable cases, 400 patients
had to be enrolled. Patient inclusion took place during
the period between July 2013 and March 2014. No inter-
ventional procedure or change in practice was required.
Measurements
Main variables of interest were BMI and blood HbA1c
level when initiating GLP-1Ra. Other study variables
included demographic characteristics (age, gender),
weight, height, arterial blood pressure, tobacco use,
latest available clinical data (year of DM2 diagnosis, year
of ﬁrst antidiabetic treatment, DM2-related complica-
tions and comorbidities) prior to GLP-1Ra treatment,
name, dosing schedule and date of ﬁrst prescription of
GLP-1Ra, HbA1c target at initiation, antidiabetic treat-
ments before initiating GLP-1Ra and simultaneously to
the GLP-1Ra and latest available biological laboratory
results (lipid and renal balance) before GLP-1Ra.
Statistical analysis
Description of study results is shown as mean (SD)
values or as percentages with ranges and/or 95% CIs, as
applicable.
Relevant statistical tests were used to compare sub-
groups depending on type of data. For categorical data,
group comparisons were performed by χ2 provided that
the number of cases for each modality was >5; otherwise,
Fisher’s exact tests were performed. For continuous
data, Student’s t-test was used after having checked for
required data assumptions.
RESULTS
In total, 403 evaluable patients were included by 53
investigators (47 endocrinologists and 6 internal medi-
cine specialists) from 24 outpatient clinics; study sites
were located at 10 out of 17 Spanish administrative
regions (autonomous communities). Patients’ character-
istics are shown in table 1. The mean (SD) age of
patients with DM2 was 58.32 (10.4) years, 205 (50.9%)
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were female and most (96.3%) were born in Spain; all
participants had to be ﬂuent in Spanish. DM2 diagnosis
was performed 9.92 (7.0) years before GLP-1Ra initi-
ation, mean age at diagnosis was 48.35 (10.3) years and
66.7% used home glucose monitoring with an average
of 8.78 (7.6) strips per week.
Most (90.8%) patients presented with at least one
current or past self-declared complication or comorbid-
ity and 47.3% were current or former smokers.
Hypertension was present in 71.2% of patients (treated
in 95.1% of them) and 70.2% had currently treated dys-
lipidaemia. Other most frequent complications or
patient-declared comorbidities included renal dysfunc-
tion (microalbuminuria in 18.4%, chronic renal insufﬁ-
ciency in 3.2%, proteinuria in 2.5%), ocular disease
(diabetic retinopathy in 13.2%), macrovascular compli-
cations (myocardial infarction or ischaemic heart
disease in 13.2%, peripheral vascular disease in 4.5% or
stroke in 3.5%) and peripheral neuropathy (5.7%).
At the time of the initiation of GLP-1Ra therapy, the
mean (SD) BMI was 36.2 (5.5) kg/m2. As shown in
table 1, most patients (93.8%) were obese and showed a
high mean waist size (114.28 cm).
Mean systolic and diastolic blood pressure values were
140.6 and 80.4 mm Hg, respectively, with 43.6% of
patients above the WHO-recommended9 cut-off for
hypertension diagnosis (>140 mm Hg systolic or
>90 mm Hg diastolic).
With regard to the drug prescribed, liraglutide was
initiated in 48.6%, lixisenatide in 35.0%, weekly exena-
tide in 12.9% and daily exenatide in 3.5% of patients
(table 2).
Fasting blood glucose at GLP-1Ra initiation was avail-
able in 92.6% of patients with a mean value of 1.77 g/L
(0.6). Mean HbA1c at GLP-1Ra initiation was 8.4% (1.4)
and in 53.6% of patients it was higher than 8%, while it
was ≤7% in 14.2% of the participants. Interestingly,
patients with HbA1c ≤7%, as compared with the rest of
the study population, had a higher mean BMI (38.7 vs
35.8, p<0.001), were more often treated only with oral
antidiabetic drugs (OADs) before GLP-1 analogue initi-
ation (70.2% vs 51.2%, p=0.0076), and more frequently
receiving OAD treatment in monotherapy (50% vs
31.6%, p=0.0279). Patients with HbA1c≤7% before initi-
ating GLP-1Ra, as compared with the rest of the study
population, were more often prescribed weekly exena-
tide (29.8% vs 10.1%, p=0.0004) and, conversely, less lix-
isenatide (14.0% vs 38.4%, p=0.0003). Also, they mostly
received GLP-1Ra in addition to OAD only (73.7% vs
53.8%, p=0.0049), and received less mixed treatment
(OAD+insulin, 22.8% vs 38.4%, p=0.0229).
With respect to the lipids proﬁle, mean values were
1.8 (0.4) g/L for total cholesterol, 0.43 (0.1) g/L for
high-density lipoprotein (HDL) cholesterol, 1.01 (0.3)
g/L for low-density lipoprotein (LDL) cholesterol and
1.95 (1.4) g/L for triglycerides (table 1).
Renal function tests showed a mean creatinine clear-
ance of 88.9 (24.1) mL/min; 42.4% of patients
Table 1 Sociodemographic and clinical characteristics
and treatments of patients before initiating GLP-1Ra
treatment
Age, years, mean (SD) 58.32 (10.4)
Sex, male, N (%) 198 (49.1)
Weight, kg, mean (SD) 97.59 (17.9)
Height, cm, mean (SD) 164.0 (10.0)
BMI, kg/m2, mean (SD) 36.22 (5.5)
Normal 18.5–25, N (%) 1 (0.2)
Overweight 25–30, N (%) 24 (6.0)
Obese ≥30, N (%) 378 (93.8)
Waist size, cm, mean (SD) 114.28 (15.0)
Systolic/diastolic blood
pressure, mm Hg, mean (SD)
140.55 (18.0)/80.35 (10.0)
Smoking habit, N (%)
Current 55 (13.6)
Former 136 (33.7)
Never smoked 212 (52.6)
Glycaemic control
Fasting blood glucose,
g/L, mean (SD)
1.77 (0.6)
HbA1c %, mean (SD) 8.41 (1.4)
HbA1c<6.5%, N (%) 24 (6.0)
HbA1c 6.5–7%, N (%) 33 (8.2)
HbA1c 7–8%, N (%) 130 (32.3)
HbA1c>8%, N (%) 216 (53.6)
Lipid parameters, mean (SD)
Total cholesterol (g/L) 1.8 (0.4)
HDL cholesterol (g/L) 0.43 (0.1)
LDL cholesterol (g/L) 1.01 (0.3)
Triglycerides (g/L) 1.95 (1.4)
Creatinine clearance,
mL/min, mean (SD)
88.9 (24.1)
Normal ≥90, N (%) 160 (46.8)
Mild renal impairment
60–90, N (%)
145 (42.4)
Moderate renal impairment
45–60, N (%)
30 (8.8)
Moderate renal impairment
30–45, N (%)
7 (2.0)
DM2 history
Time since diagnosis
(years), mean (SD)
9.91 (7.0)
Age at diagnosis (years),
mean (SD)
48.35 (10.3)
Time between DM2 diagnosis and first treatment, N (%)
Concomitant 261 (81.1)
1 year 18 (5.6)
1–5 years 31 (9.6)
>5 years 12 (3.7)
Antidiabetic treatment before/after initiation of GLP-1Ra
OAD only, N (%) 217 (53.8)/223 (55.3)
OAD only, 1 drug, N (%) 76 (35.0)/0
OAD only, 2 drugs, N (%) 83 (38.2)/145 (65.0)
OAD only, 3 drugs, N (%) 52 (24.0)/71 (31.8)
OAD only, ≥4 drugs, N (%) 6 (2.8)/7 (3.1)
Insulin only, N (%) 21 (5.2)/29 (7.2)
OAD+insulin, N (%) 161 (40.0)/146 (36.2)
No antidiabetic drugs,
N (%)
4 (1.0)/5 (1.2)
BMI, body mass index; DM2, type 2 diabetes mellitus; GLP-1Ra,
glucagon-like peptide-1 receptor agonists; HbA1c, glycated
haemoglobin; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; OAD, oral antidiabetic drug.
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presented with mild (60–90 mL/min) and 10.8% with
moderate (30–60 mL/min) renal impairment (table 1).
The ﬁrst use of antidiabetic drugs was usually con-
comitant to diagnosis (81.1% of patients). At study visit,
before GLP-1Ra initiation, 53.8% of patients were receiv-
ing only an OAD treatment and 40% had a mixed treat-
ment with insulin and OAD. In total, 5.2% were only
treated by insulin. Of patients only on OAD, most were
treated with two drugs (38.2%) or a single drug (35%),
and 24% received triple therapy (table 1).
At GLP-1Ra initiation, the most frequent (90.7% of
patients) individualised HbA1c target was 7%; however,
this could only be recorded from 33% of study participants.
GLP-1Ra were mostly prescribed without any change in the
main classes of previous antidiabetic therapies (table 1). In
addition to the GLP-1Ra, more than half of the patients
(55.3%) received only an OAD, 36.2% had a mixed treat-
ment with insulin and OAD, and only 7.2% were treated
with insulin without OAD. Mainly, types of antidiabetic
treatments prescribed with the GLP-1Ra were similar to
those used before its initiation (table 3), but some patients
already treated with three drugs stopped one of their OAD
(most frequently dipeptidyl peptidase-4 inhibitors). Finally,
the GLP-1Ra were most frequently prescribed with two
OAD (65%) or with three OAD (31.8%); some patients
(3.1%) received four different OAD or more.
DISCUSSION
This study provides demographic and clinical proﬁles of
patients with DM2 at the time of initiation of treatment
with GLP-1Ra, as well as drug treatment for DM2 before
and after initiation of GLP-1Ra in real-life clinical prac-
tice in Spain. Study investigators were all specialists
(endocrinology and internal medicine) representing the
usual setting where GLP-1Ra treatments are initiated in
Spain, and participating centres were spread across the
country covering 10 out of 17 administrative regions
(autonomous communities). Thus, it seems reasonable
to assume that the study sample is fairly representative of
the overall country population of patients with DM2 who
were being prescribed GLP-1Ra for the ﬁrst time during
the study period.
Patients’ characteristics differ somehow from the
average DM2 Spanish population, as compared with
recent epidemiological data.10–12 Our patients were
younger (58.3 years), with just a slightly higher propor-
tion of females (50.9%), more with obesity (93.8%) and
high mean BMI (36.2 kg/m2), as well as mean arterial
blood pressure (140.6/80.4 mm Hg); more showed renal
dysfunction (53.2%) and poor lipid balance (HDL chol-
esterol <0.5 g/L and LDL cholesterol ≥1 g/L); also,
time since DM2 diagnosis was longer (9.9 years) and
almost all participants were on antidiabetic pharmaco-
logical treatment before initiating GLP-1Ra. Glycaemic
control was also poor with mean fasting glycaemia of
1.8 g/L and 85.9% of participants showing HbA1c>7%.
Since the reason for treatment change was not recorded
(eg, poor tolerability, compliance issues, patient’s
request, etc), the reasons for prescribing GLP-1Ra to
patients with HbA1c≤7% (14.1%) cannot be fully ascer-
tained. However, there are several intriguing ﬁndings
(higher use of weekly exenatide, lower use of lixisena-
tide, higher BMI, higher use of OAD therapy in addition
to the GLP-1Ra) that could suggest an aim of weight loss
as a primary driver for use, rather than pursuing more
glycaemic control with weight loss being an added
beneﬁt. In addition, with regional payers in Spain limit-
ing reimbursed prescription of GLP-1Ra to patients with
BMI above 30 (or 35 kg/m2 in some regions) and with
Table 3 OAD used before and after GLP-1Ra treatment
initiation
n=217 n=223
Number of OAD
Before
GLP-1Ra
With
GLP-1Ra
1 76 (35.0%) 0
2 83 (38.2%) 145 (65.0%)
3 52 (24.0%) 71 (31.8%)
>3 6 (2.8%) 7 (3.1%)
Mean number of OAD
(SD)
1.94 (0.8) 2.39 (0.6)
Biguanide
Metformin 199 (91.7%) 214 (96.0%)
Sulfonylurea
Gliclazide 47 (21.7%) 41 (18.4%)
Glimepiride 21 (9.7%) 18 (8.1%)
Glibenclamide 9 (4.1%) –
Other 2 (1.0%) 2 (0.8%)
DPP-4 inhibitor
Sitagliptin 57 (26.3%) 2 (0.9%)
Vildagliptin 33 (15.2%) 3 (1.3%)
Other 8 (3.7%) 1 (0.4%)
Mitiglinide
Repaglinide 30 (13.8%) 15 (6.7%)
Glitazone
Pioglitazone 13 (6.0%) 11 (4.9%)
α glucosidase inhibitor
Acarbose 1 (0.5%) –
DPP-4, dipeptidyl peptidase-4; GLP-1Ra, glucagon-like peptide-1
receptor agonists; OAD, oral antidiabetic drug.
Table 2 GLP-1Ra (glucagon-like peptide-1 receptor
agonists) initiated and unit dose
GLP-1Ra Dose
Number of patients
(% for each drug)
Liraglutide 0.6 mg 29 (14.8)
1.2 mg 126 (64.3)
1.8 mg 41 (20.9)
Lixisenatide 10 µg 43 (30.5)
20 µg 98 (69.5)
Weekly exenatide 2 mg 52 (100)
Exenatide 5 µg 1 (7.1)
10 µg 13 (92.9)
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so much emphasis put on the weight reduction potential
of this class of drugs, the possibility that this has become
a major factor for use in this subgroup cannot be ruled
out.
With respect to antidiabetic treatment prior to
GLP-1Ra initiation, a proportion of study participants
were receiving insulin, either in combination with OAD
or as single treatment. Compared with the average
patient with DM2 in Spain, this proportion (45%) is
remarkably higher than recently published data
(23%),10 further reﬂecting that the patients’ proﬁles
from our study population represent a subset of DM2
individuals with a longer duration of the disease, who
are less responsive to antidiabetic treatment, with a
more severe disease course and/or less compliant with
disease management, among other possible explana-
tions. All the above characteristics seem to describe a
typical patient with DM2 with a longer disease course,
more risk factors (obesity and high BMI) and more
diabetes-related comorbidities (hypertension, renal dys-
function, hyperlipidaemia) than in the average patient
with DM2. In Spain, indications for use of GLP-1Ra, as
described in the approved prescribing information,13–16
recommend its use when patients do not achieve gly-
caemic control with full doses of any, among various,
OAD without mentioning other speciﬁc patients’
characteristics or restrictions (except for moderate or
severe renal dysfunction, hepatic impairment and use in
children). However, these data show that Spanish physi-
cians are initiating GLP1-Ra mostly in advanced DM2
cases, especially in overweight or obese individuals,
reﬂecting current Spanish regional payers’ restrictions
on GLP-1Ra reimbursed prescription only to patients
with a BMI>30 or >35 kg/m2. In terms of duration of
diabetes, this would appear to be in contrast with some
recent physician survey in the UK,8 where it would
appear that GLP-1Ra are used in patients with a shorter
duration of diabetes. In that survey, the importance of
the need for further glycaemic control and weight loss is
in line with the ﬁndings of the present study.
With respect to the choice of GLP-1Ra among available
drugs in Spain at the time this study was conducted, it
should be noticed that two compounds from this class
were launched while this study was recruiting patients,
weekly exenatide, followed by lixisenatide some time later.
Despite its apparent advantage with weekly dosing versus
other GLP-1Ra, weekly exenatide was prescribed to 13% of
study participants while lixisenatide, which requires daily
injections, was initiated in 35% of patients. Liraglutide,
older in the market and also administered as daily injec-
tions, was also highly (49%) prescribed during this study.
This, together with the substantial number of individuals
receiving insulin in combination with GLP-1Ra, could
explain why GLP-1Ra compounds which are approved to
be used in combination with insulin, such as lixisenatide
and liraglutide, were prescribed more often in this cohort.
Real-life studies are deemed necessary to complement
information retrieved with clinical trials. Both have
limitations and should be seen as complementary. It is
important to understand the strengths and weaknesses
of both approaches. The choice of the investigators, the
lack of a centralised laboratory, the lack of intensive
monitoring among others, hamper the internal validity
of real-life studies. The sites and investigators for this
study were selected on the basis of being current users
of GLP-1Ra and being able to achieve reasonably short
start-up times. However, the number of sites and the fact
that more than 50% of the Spanish autonomous com-
munities (including those with larger populations) were
included should provide a fair representativeness of the
country’s reality. Owing to the existence of payers’
restrictions to GLP-1Ra use in Spain, ﬁrst prescription of
these compounds by the primary care physicians was
clearly minor at the time of conducting the study.
Hence, the predominance of specialist sites may have
resulted in some patient selection bias towards a more
advanced, complex patient type. However, most guide-
lines and algorithms tend to place GLP-1Ra late in the
course of the disease, mainly for cost reasons, and most
pivotal clinical trials of currently available studies have
been conducted with patients with a long duration of
diabetes, so the bias may not have had as much impact
as could be anticipated.
On the other hand, this study is the ﬁrst effort to assess
the clinical and sociodemographic proﬁle of patients
receiving an initial prescription of GLP-1Ra in Spain, in a
relevant number of patients and sites. Moreover, its cross-
sectional nature brings a new and different perspective
since the published data so far come from retrospective
analyses of databases mostly aiming at assessing compara-
tive efﬁcacy, or from physician surveys providing percep-
tions of what is behind the decision to prescribe or not a
GLP-1Ra. As such, it should provide valuable insight in
learning about such treatment patterns.
In conclusion, this study provides an updated descrip-
tion of patients with DM2 initiating GLP-1Ra treatment
in Spain. Their worse than average clinical picture of
patients with DM2 probably reﬂects clinicians’ behaviour
towards limiting GLP-1Ra to more advanced disease,
consistent with payers’ restrictions but potentially not
totally aligned with the mechanistic background (which
would call probably for use earlier in the course of the
disease). Also, it may be worth reﬂecting further on
whether emphasis being placed on the weight loss prop-
erties of this class of drugs is leading to somewhat forget-
ting that the primary aim of their use should be, in line
with the approved indications, improving glycaemic
control, with weight loss as a highly desirable added
beneﬁt, rather than their major feature.
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